Evolution Research Group, LLC Appoints Bernadette D’Souza, MD as Chief Scientific Officer
January 16, 2017
Effective, January 2, 2017, Bernadette D’Souza, MD, will assume the position of Chief Scientific Officer (CSO) of Evolution Research Group, LLC (ERG). Dr. D’Souza, a highly-respected Principal Investigator and Founder of Midwest Clinical Research Center, LLC (MCRC) will continue to support the team at MCRC led by Otto Dueno, MD, Medical Director and Melissa Ellis, Site Director, but will now also assume additional responsibilities, including client liaison and consulting activities.
Dr. D’Souza is extremely enthusiastic about this new role stating “Accepting the position of CSO at ERG was not difficult for me. The opportunity to work closely with some of the most dedicated people on both sides of the aisle in drug development was something I could not pass up. I have many years of clinical research experience and love networking.” As a member of the ERG senior management team, D’Souza believes that “Together with an outstanding CEO and CMO at ERG, I am confident we have a lot to contribute to the development of new medications for the treatment of many medical indications.”
Dr. Rick Mofsen, Chief Medical Officer at ERG is looking forward to working more closely with D’Souza and collaborating with her on many levels. When told that D’Souza accepted the role, Mofsen stated, “Dr. D’Souza has always been regarded to be one of the finest PI’s in neuroscience and as a PI, I always enjoyed working with her at ERG. In her new role as CSO, we now have the opportunity to collaborate on a different level which will surely deliver many enhancements to the process of new drug development.”
ERG owns and operates seven specialty inpatient and outpatient, early and late phase research units and manages a network of 10 affiliate research sites. The company’s CEO, Lori Wright commented “We are thrilled to have Bernadette continue on with ERG in this newly created role. Our PIs, Site Directors, Business Development Account Directors and the senior management team members have a tremendous amount of respect for her. We carefully transferred her PI responsibilities to Dr. Dueno over the past year, allowing her more time to devote to interacting with our clients who have expressed interest in having greater access to her experience, knowledge and enthusiasm for drug development.”
The company established itself as a leader in CNS research and has now expanded into many other therapeutic areas. Conducting some of the most complex clinical trials in highly specialized populations, ERG knows the importance of quality, compliance and patient safety. Ms. Wright is proud of her leadership team and went on to add “We feel very fortunate to have Dr. D’Souza and Dr. Mofsen, two well-known and respected industry veterans, leading our clinical and medical activities. To have the two of them working alongside Andria Chastain, Sr. Vice President of Clinical Operations, and Barbara Smallwood, Vice President of Quality, gives me tremendous confidence as we continue to grow the company and assist our sponsors in advancing the development of much needed new medications.”